Market reactionShares fell 10% on Nov 5.
Achieve Life Sciences is a late-stage company developing cytisinicline, a plant-based treatment to help adults quit smoking and vaping; it is not approved.
Achieve's case rests on cytisinicline for smoking cessation, where a June FDA complete response letter cited manufacturing observations and unfinished labeling, not efficacy or safety. Achieve has moved manufacturing to Adare Pharma Solutions and plans to resubmit in the fourth quarter of 2026, expecting approval in the first half of 2027. Cash was $187.3 million at June 30, with up to $174 million more from warrants exercisable until shortly after approval.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Achieve resubmits with Adare in the fourth quarter
Does Achieve resubmit on time with a complete manufacturing package from Adare?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Achieve plans to resubmit its cytisinicline NDA in the fourth quarter with Adare as manufacturer, after a June complete response letter cited only manufacturing and labeling; it expects approval in the first half of 2027 and had $187.3 million at June 30
Cytisinicline cleared the clinical bar but hit a manufacturing wall; Q4 resubmission with new CMO determines whether a $354M bet pays off
Cytisinicline's Q4 resubmission must clear the CRL's manufacturing and labeling issues before a potential 2027 launch
FDA issues cytisinicline CRL over manufacturing observations and unfinished labeling
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
vs. direct competitors
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.